MorningMed is a community of 814,300 medical professionals

We're a place where medical professionals share news and other news items to help their peers stay up to date

All articles tagged: Unspecified B-cell lymphoma, intrathoracic lymph nodes (C85.12)

HealthDay 14 June at 03.35 PM

Second Tumors Are Rare After Chimeric Antigen Receptor T-Cell Therapy

Second tumors are rarely seen after chimeric antigen receptor (CAR) T-cell therapy, according to a study published in the June 13 issue of the New England Journal of Medicine.Mark P. Hamilton, M.D., Ph.D., from Stanford University in California, and colleagues examined the occurrence of second tumors after CAR T-cell therapy since 2016.

Evalytics 19 March at 06.04 AM

FDA Approves First CAR T-Cell Therapy for rrCLL, rrSLL

The FDA has granted accelerated approval for lisocabtagene maraleucel (liso-cel), a CAR T-cell therapy, in certain adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Developed by Juno Therapeutics, the therapy, branded as Breyanzi, targets CD19 and is approved for patients who've undergone at least two prior lines of therapy, including specif

HealthDay 21 December at 04.47 PM

American Society of Hematology, Dec. 9 to 12

The annual meeting of the American Society of Hematology was held from Dec. 9 to 12 in San Diego and attracted participants from around the world, including hematology specialists as well as clinical practitioners and other health care professionals. The conference featured presentations focusing on the diagnosis, treatment, and

HealthDay 12 December at 03.58 PM

ASH: Axi-Cel CAR T-Cell Treatment Effective in High-Risk Lymphoma Patients

For patients with relapsed or refractory large B-cell lymphoma, including those with comorbidities, the autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel) yields five-year progression-free survival (PFS) of 28.5 percent and overall survival of 40.3 percent, according to a study presented at the annual